Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer

•Median PFS was significantly longer with alectinib versus chemotherapy.•ORR and CNS ORR (in patients with measurable baseline CNS lesions) were higher with alectinib than chemotherapy (P < 0.001).•The safety profile of alectinib was consistent with the primary analysis and post-marketing experience.•Alectinib demonstrated activity against several secondary ALK mutations detected in baseline plasma.•Alectinib prolonged PFS versus chemotherapy in patients with wild-type or mutant TP53, and a prognostic difference was seen.